Michael Hopen, MD
Ophthalmology · Carmel, INNPI 1689993347
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.1%), speaking fees and gifts — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Sight Sciences, Inc. at 34.9% of the total. 2025 is the largest year on record at $4,606, 3.2 times the $1,440 reported in 2019. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $40.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$4K
- Glaukos Corporation$2K
- Alcon$2K
- AbbVie$729
- Lensar, Inc.$487
- Bausch & Lomb Americas Inc.$429
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$4,50041%
- Travel & lodging$390%
- Food & beverage$6,34858%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 10 | $3,818 |
| Glaukos Corporation | 15 | $1,843 |
| Alcon | 69 | $1,780 |
| AbbVie(2 entities) | 55 | $729 |
| Lensar, Inc. | 3 | $487 |
| Bausch & Lomb Americas Inc. | 26 | $429 |
| Novartis | 13 | $243 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $204 |
| Oyster Point Pharma, Inc. | 10 | $201 |
| Thea Pharma Inc. | 8 | $144 |
| NEW World Medical,inc. | 7 | $138 |
| Biotissue Holdings Inc. | 6 | $135 |
| Harrow Eye, LLC | 4 | $122 |
| Sun Pharmaceutical Industries Inc. | 6 | $113 |
| Tarsus Pharmaceuticals, Inc. | 3 | $108 |
| Ivantis, Inc | 4 | $67 |
| Ocular Therapeutix, Inc. | 3 | $55 |
| Kala Pharmaceuticals, Inc. | 3 | $46 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $45 |
| Shire North American Group Inc | 3 | $44 |
| Aerie Pharmaceuticals, Inc. | 2 | $43 |
| Nova Eye, Inc. | 1 | $27 |
| Dompe US, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Rxsight Inc | 1 | $18 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Amgen | 1 | $13 |
| Eyepoint US, Inc. | 1 | $12 |
| Johnson & Johnson Vision Care, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$3,632
- SION SURGICAL INSTRUMENT$3,632
- iStent inject Trabecular Micro-Bypass Stent System$1,109
- iStent Trabecular Micro-Bypass Stent System$1,000
- Hydrus Microstent$577
- LENSAR LASER SYSTEM$387
- iStent infinite Trabecular Micro-Bypass System Model iS3$345
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$173
How this compares
$10,932 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 253 | $155,333 |
| LumiganBimatoprost | 217 | $128,761 |
| RestasisCyclosporine | 73 | $85,359 |
| XiidraLifitegrast | 53 | $57,670 |
| VyzultaLatanoprostene Bunod | 98 | $50,725 |
| Prednisolone Acetate | 877 | $38,637 |
| RhopressaNetarsudil Mesylate | 32 | $21,940 |
| Brimonidine Tartrate | 464 | $19,679 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 98 | $15,249 |
| CombiganBrimonidine Tartrate/Timolol | 40 | $15,232 |
| Timolol Maleate | 378 | $14,974 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 51 | $14,086 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,096 | $13,842 |
| Cyclosporine | 23 | $13,620 |
| Latanoprost | 1,050 | $12,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Restasis Multidose, Alphagan P | $729 | $247,645361 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $43 | $177,273285 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $429 | $108,395151 claims |
| AlconSimbrinza | $1,780 | $14,08651 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $201 | $6,22611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Carmel
- Michael BehforouzCarmel$17K
- Neil FinnenCarmel$10K
- Thomas CiullaCarmel$7K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.